282087-44-9

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
4-Iodo-3-methoxybenzenecarboxylic acid serves as a crucial intermediate in the synthesis of various pharmaceutical and agrochemical products. Its unique structure allows for the development of new compounds with potential therapeutic or pesticidal properties, contributing to advancements in healthcare and agriculture.
Used in Dye and Pigment Production:
In the dye and pigment industry, 4-Iodo-3-methoxybenzenecarboxylic acid is utilized in the creation of a range of colorants. Its molecular structure, which includes an iodine atom and a methoxy group, endows it with characteristics that are valuable for producing dyes and pigments with specific color profiles and properties.
Used in Organic Synthesis:
4-Iodo-3-methoxybenzenecarboxylic acid is employed as a building block in organic synthesis. The presence of the carboxylic acid group in its structure makes it a suitable candidate for the attachment of other functional groups, enabling the synthesis of a wide range of derivatives. These derivatives can be tailored for specific applications, such as the development of new materials or the improvement of existing ones.

Upstream product

• 39896-53-2 4-(3'-Methoxy-4'-iodphenyl)-DL-isovalin 
• 39896-41-8 5-(3-methoxy-phenethyl)-5-methyl-imidazolidine-2,4-dione 
• 35387-92-9 methyl 4-iodo-3-methoxybenzoate 
• 58123-77-6 3-hydroxy-4-iodobenzoic acid 
• 41608-64-4 methyl 3-methoxy-4-aminobenzoate 
• 5081-37-8 methyl 3-methoxy-4-nitrobenzoate 
• 5081-36-7 3-methoxy-4-nitrobenzoic acid 
• 2486-69-3 3-methoxy-4-aminobenzoic acid 
• 39896-47-4 4-(3'-Methoxyphenyl)-DL-isovalin 
• 586-38-9 3-Methoxybenzoic acid 
• 186583-59-5 1-iodo-2-methoxy-4-methylbenzene 

Downstream Products

• 1231960-83-0 4-iodo-3-methoxy-benzoyl chloride 
• 1202057-10-0 tert-butyl 4-iodo-3-methoxybenzoate 
• 933585-54-7 4-iodo-3-(methyloxy)benzamide 
• 1202055-53-5 4-({3-[(2,6-diethylphenyl)carbamoyl]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazolin-8-yl}amino)-3-methoxybenzoic acid 
• 1202055-50-2 tert-butyl 4-({3-[(2,6-diethylphenyl)carbamoyl]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazolin-8-yl}amino)-3-methoxybenzoate 
• 1202055-89-7 N-(2,6-diethylphenyl)-8-({2-methoxy-4-[(4-methyl-1,4-diazepan-1-yl)carbonyl]phenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide 
• 1202055-66-0 N-(2,6-diethylphenyl)-8-[(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}-2-methoxyphenyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide 
• 1202055-67-1 N-(2,6-diethylphenyl)-8-[(2-methoxy-4-{[(2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl}phenyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide 
• 1202055-68-2 N-(2,6-diethylphenyl)-8-[(2-methoxy-4-{[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl}phenyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide 
• 1202055-60-4 N-(2,6-diethylphenyl)-8-[(4-{[2-(dimethylamino)ethyl]carbamoyl}-2-methoxyphenyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide 
• 1202055-34-2 N-(2,6-diethylphenyl)-8-({2-methoxy-4-[(1-methylpiperidin-4-yl)carbamoyl]phenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide 
• 1202055-59-1 8-[(4-carbamoyl-2-methoxyphenyl)amino]-N-(2,6-diethylphenyl)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide 
• 1202057-13-3 4-iodo-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide 

Relevant academic research and scientific papers

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor

Monoacylglycerol lipase (MAGL) is the enzyme degrading the endocannabinoid 2-arachidonoylglycerol, and it is involved in several physiological and pathological processes. The therapeutic potential of MAGL is linked to several diseases, including cancer. The development of MAGL inhibitors has been greatly limited by the side effects associated with the prolonged MAGL inactivation. Importantly, it could be preferable to use reversible MAGL inhibitors in vivo, but nowadays only few reversible compounds have been developed. In the present study, structural optimization of a previously developed class of MAGL inhibitors led to the identification of compound 23, which proved to be a very potent reversible MAGL inhibitor (IC50 = 80 nM), selective for MAGL over the other main components of the endocannabinoid system, endowed of a promising antiproliferative activity in a series of cancer cell lines and able to block MAGL both in cell-based as well as in vivo assays.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

Discovery of biphenylacetamide-derived inhibitors of BACE1 using de novo structure-based molecular design

β-Secretase (BACE1), the enzyme responsible for the first and rate-limiting step in the production of amyloid-β peptides, is an attractive target for the treatment of Alzheimer's disease. In this study, we report the application of the de novo fragment-based molecular design program SPROUT to the discovery of a series of nonpeptide BACE1 inhibitors based upon a biphenylacetamide scaffold. The binding affinity of molecules based upon this designed molecular scaffold was increased from an initial BACE1 IC50 of 323 μM to 27 μM following the synthesis of a library of optimized ligands whose structures were refined using the recently developed SPROUT-HitOpt software. Although a number of inhibitors were found to exhibit cellular toxicity, one compound in the series was found to have useful BACE1 inhibitory activity in a cellular assay with minimal cellular toxicity. This work demonstrates the power of an in silico fragment-based molecular design approach in the discovery of novel BACE1 inhibitors.

Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors

The synthesis and SAR of a series of novel pyrazolo-quinazolines as potent and selective MPS1 inhibitors are reported. We describe the optimization of the initial hit, identified by screening the internal library collection, into an orally available, potent and selective MPS1 inhibitor.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS

The present invention relates to substituted pyrrolyl-pyrimidines which modulate the activity of protein kinases and are therefore useful in treating diseases caused by dysregulated protein kinase activity, in particular MPS1. The present invention also p

METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS

A method of treatment using pharmaceutical compositions containing novel antagonists or inverse agonists at opioid receptors for the treatment of binge eating disorder, anorexia nervosa, bulimia nervosa, excess drug or alcohol use, or eating disorder not otherwise specified.